Thymosin beta 4 ameliorates hyperglycemia and improves insulin resistance of KK Cg-Ay/J mouse

Diabetes Research and Clinical Practice

Volumn 96, Issue 1, 2012, Pages 53-59

  Zhu, Jian ^a   Su, Li Ping ^b   Ye, Lei ^c   Lee, Kok Onn ^b   Ma, Jian Hua ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Diabetes mellitus; Insulin resistance; Thymosin beta 4

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GAMMA INTERFERON; HEMOGLOBIN A1C; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; THYMOSIN BETA4; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; ENZYME ACTIVITY; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HORMONE BLOOD LEVEL; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT CHANGE;

ANIMALS; BLOTTING, WESTERN; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN RESISTANCE; MICE; THYMOSIN;

EID: 84858752245     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.12.009     Document Type: Article

References (30)

1. Chen G., Lai X., Jiang Q., Chen F., Chen N., Huang H., et al. Cardiovascular disease (CVD) risk, insulin resistance and beta-cell function in prehypertension population of China. Atherosclerosis 2011, 217:279-285.
2. Godsland I.F., Lecamwasam K., Johnston D.G. A systematic evaluation of the insulin resistance syndrome as an independent risk factor for cardiovascular disease mortality and derivation of a clinical index. Metabolism 2011, 60:1428-1442.
3. Reddy K.J., Singh M., Bangit J.R., Batsell R.R. The role of insulin resistance in the pathogenesis of atherosclerotic cardiovascular disease: an updated review. J Cardiovasc Med (Hagerstown) 2010, 11:633-647.
4. Winterstein A.G. Rosiglitazone and the risk of adverse cardiovascular outcomes. Clin Pharmacol Ther 2011, 89:776-778.
5. Crockford D., Turjman N., Alan C., Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci 2010, 1194:179-189.
6. Hinkel R., Bock-Marquette I., Hatzopoulos A.K., Kupatt C. Thymosin beta4: a key factor for protective effects of eEPCs in acute and chronic ischemia. Ann N Y Acad Sci 2010, 1194:105-111.
7. Smart N., Risebro C.A., Clark J.E., Ehler E., Miquerol L., Rossdeutsch A., et al. Thymosin beta4 facilitates epicardial neovascularization of the injured adult heart. Ann N Y Acad Sci 2010, 1194:97-104.
8. Shrivastava S., Srivastava Olson E.N., DiMaio J.M., Bock-Marquette I. Thymosin beta4 and cardiac repair. Ann N Y Acad Sci 2010, 1194:87-96.
9. Tokura Y., Nakayama Y., Fukada S., Nara N., Yamamoto H. Matsuda R, and Hara T. Muscle injury-induced thymosin beta4 acts as a chemoattractant for myoblasts. J Biochem 2011, 149:43-48.
10. Ye L., Lee K.O., Su L.P., Toh W.C., Haider H.K., Law P.K., et al. Skeletal myoblast transplantation for attenuation of hyperglycaemia, hyperinsulinaemia and glucose intolerance in a mouse model of type 2 diabetes mellitus. Diabetologia 2009, 52:1925-1934.
11. Saghizadeh M., Kramerov A.A., Tajbakhsh J., Aoki A.M., Wang C., Chai N.N., et al. Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas. Invest Ophthalmol Vis Sci 2005, 46:3604-3615.
12. Sosne G., Qiu P., Kurpakus-Wheater M., Matthew H. Thymosin beta4 and corneal wound healing: visions of the future. Ann N Y Acad Sci 2010, 1194:190-198.
13. Dunn S.P., Heidemann D.G., Chow C.Y., Crockford D., Turjman N., Angel J., et al. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4. Ann N Y Acad Sci 2010, 1194:199-206.
14. Iwatsuka H., Shino A., Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol Jpn 1970, 17:23-35.
15. Hemmingsen B., Lund S.S., Wettersle, Jnd Vaag A. Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes. Eur J Endocrinol 2009, 161:1-9.
16. Everett B.M., Cook N.R., Magnone M.C., Bobadilla M., Kim E., Rifai N., et al. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's health study. Circulation 2011, 123:2811-2818.
17. Bitzur R. Diabetes and cardiovascular disease: when it comes to lipids, statins are all you need. Diabetes Care 2011, 34(Suppl. 2):S380-S382.
18. Bloomgarden Z.T. Diabetes and cardiovascular disease. Diabetes Care 2011, 34:e24-e30.
19. Semenkovich C.F. Insulin resistance and atherosclerosis. J Clin Invest 2006, 116:1813-1822.
20. Nigro J., Osman N., Dart A.M., Little P.J. Insulin resistance and atherosclerosis. Endocr Rev 2006, 27:242-259.
21. Bock-Marquette I., Saxena A., White M.D., Dimaio J.M., Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004, 32:466-472.
22. Zhu J., Yong W., Wu X., Yu Y., Lv J., Liu C., et al. Anti-inflammatory effect of resveratrol on TNF-alpha-induced MCP-1 expression in adipocytes. Biochem Biophys Res Commun 2008, 369:471-477.
23. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867.
24. Maybee N.A., Worrall B.B., Nadler J.L. Is anti-inflammatory therapy for type 2 diabetes mellitus ready for routine clinical practice. Nat Clin Pract Endocrinol Metab 2007, 3:806-807.
25. Young J.D., Lawrence A.J., MacLean A.G., Leung B.P., McInnes I.B., Canas B., et al. Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 1999, 5:1424-1427.
26. Sosne G., Qiu P., Christopherson P.L., Wheater M.K. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res 2007, 84:663-669.
27. Farese R.V., Sajan M.P., Standaert M.L. Atypical protein kinase C in insulin action and insulin resistance. Biochem Soc Trans 2005, 33:350-353.
28. Chambers M.A., Moylan J.S., Smith J.D., Goodyear L.J. Reid MB.Stretch-stimulated glucose uptake in skeletal muscle is mediated by reactive oxygen species and p38 MAP-kinase. J Physiol 2009, 587:3363-3373.
29. DeFronzo R.A., Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 2009, 32:S157-S163.
30. Mora C.A., Baumann C.A., Paino J.E., Goldstein A.L., Badamchian M. Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice. Int J Immunopharmacol 1997, 19:1-8.